Abstract
Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Current Alzheimer Research
Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Volume: 2 Issue: 5
Author(s): Lon S. Schneider, Steven T. DeKosky, Martin R. Farlow, Pierre N. Tariot, Robert Hoerr and Meinhard Kieser
Affiliation:
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Abstract: Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Export Options
About this article
Cite this article as:
Schneider S. Lon, DeKosky T. Steven, Farlow R. Martin, Tariot N. Pierre, Hoerr Robert and Kieser Meinhard, A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type, Current Alzheimer Research 2005; 2 (5) . https://dx.doi.org/10.2174/156720505774932287
DOI https://dx.doi.org/10.2174/156720505774932287 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Current Neuropharmacology High Throughput Binding Analysis Determines the Binding Specificity of ASF/SF2 on Alternatively Spliced Human Pre-mRNAs
Combinatorial Chemistry & High Throughput Screening Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Current Alzheimer Research A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Cognitive and Cardiovascular Benefits of Docosahexaenoic Acid in Aging and Cognitive Decline
Current Alzheimer Research Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Amyloid Aggregation Inhibitory Mechanism of Arginine-rich D-peptides
Current Medicinal Chemistry Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design FDG-PET Studies of Semantic Dementia; A Review
Current Molecular Imaging (Discontinued) Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs
Infectious Disorders - Drug Targets Wound Healing Effects of Curcumin: A Short Review
Current Pharmaceutical Biotechnology A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry